{"id":"gsk-573719-62-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing muscarinic M3 receptors on airway smooth muscle, GSK573719 prevents acetylcholine-induced bronchoconstriction and promotes sustained airway relaxation. This mechanism is characteristic of anticholinergic bronchodilators used in chronic obstructive pulmonary disease (COPD) management. The long-acting formulation provides once-daily or twice-daily dosing for maintenance therapy.","oneSentence":"GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:36.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT01328444","phase":"PHASE3","title":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":349},{"nctId":"NCT01641692","phase":"PHASE2","title":"A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05","conditions":"Asthma","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low Dose 719"],"phase":"phase_3","status":"active","brandName":"GSK 573719 62.5","genericName":"GSK 573719 62.5","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}